中
  • Home
  • About Us

    • Company Overview
    • R&D Leader
    • R&D Team
    • Board of Directors
    • Partners
  • R&D

    • R&D Strategy
    • Medical Information
  • Pipeline

    • TGRX-678 BCR-ABL inhibitor
    • TGRX-326 ALK/ROS1 inhibitor
    • TGRX-814 BCL2 inhibitor
  • News

  • Partnering

  • Careers

    • Opportunities
    • Company Culture
  • Contact

    • Contact Us
    • Message

R&D

Mission drives innovation, and innovation improves quality of life

Medical Information

  • TargetRx's world-class R&D platform2021-10-14 Views:523

    Drugs Targeting at Allosteric & Orthosteric SitesWe make full use of the advantages of allosteric and orthosteric ...

  • [In-depth Report] BCR-ABL1 allosteric inhibitor symbolizes a new start oftargeted therapy2021-10-15 Views:448

    Allosteric regulation is ubiquitous in the life processes of cells, including non-covalent interactions between mole ...

About Us

R&D

Pipeline

News

Partnering

Careers

Contact

  • Tel: +86-0755-86934300
  • 3rd Floor, Building A1, Kexing Science Park, No. 15 Keyuan Rd., Nanshan District, Shenzhen, China
  • E-mail: targetrx@tjrbiosciences.com

Follow Us

  • Tel: +86-0755-86934300
  • 3rd Floor, Building A1, Kexing Science Park, No. 15 Keyuan Rd., Nanshan District, Shenzhen, China
  • E-mail: targetrx@tjrbiosciences.com
Copyright © 2021 Shenzhen TargetRx, Inc.
粤ICP备2021119553号